Visual analysis of intravenous thrombolytic drugs for acute ischemic stroke
- VernacularTitle:静脉溶栓药物治疗急性缺血性卒中的可视化分析
- Author:
Yumeng LIU
1
;
Baoqiang ZHU
2
;
Tingting JIANG
1
;
Yanping LI
1
;
Ni ZHANG
1
;
Yuanlin WU
1
;
Yao LIU
1
Author Information
1. Dept. of Pharmacy，Daping Hospital，Army Medical University，Chongqing 400042，China
2. School of Pharmacy，Southwest Medical University，Sichuan Luzhou 646000，China
- Publication Type:Journal Article
- Keywords:
intravenous thrombolytic drug;
ischaemic stroke;
visual analysis;
third generation of intravenous tissue
- From:
China Pharmacy
2024;35(10):1243-1248
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the research status， hotspots and trends in the research of intravenous thrombolytic drugs in the treatment of acute ischemic stroke. METHODS The original studies related to intravenous thrombolytic drugs for acute ischemic stroke were collected by searching the Web of Science core database； the authors， countries/regions， institutions and keywords of the literature were visualized and analyzed using CiteSpace 6.1.R6 software. RESULTS A total of 1 810 articles were included， and the number of articles published showed an increasing trend year by year， with the United States （556 articles） having the largest number of articles， and China ranking the second （339 articles， with centrality of 0）. The most published author was Ahmed of Sweden （32 articles）， and the most published institution was the University of Calgary in Canada （80 articles）. The current research status and hotspots were mainly the application and therapeutic exploration of new thrombolytic drugs， and the frontier and development trend were the adverse prognosis of neurological deterioration and hemorrhagic transformation accompanied by intravenous thrombolytic drug treatment. CONCLUSIONS The research hotspots and frontier about intravenous thrombolytic drugs for acute ischemic stroke are mainly the third generation of intravenous tissue plasminogen activator， and the exploration of new intravenous thrombolytic drugs and their safety and effectiveness will be the future research hotspots. Chinese scholars and research teams should strengthen cooperation and exchanges with other countries， which can be strengthened by carrying out multi-center clinical trials.
